Novo Holdings to Acquire Catalent for $16.5 Billion to Bolster Novo Nordisk’s Semaglutide Production Capacity

On February 5, Novo Nordisk announced that its controlling shareholder, Novo Holdings, had entered into a merger and acquisition agreement with Catalent. Novo Holdings will acquire Catalent for $16.5 billion in cash.As part of the transaction, Novo Nordisk will acquire three Catalent fill-finish sites from Novo Holdings for $11 billion to boost the production capacity of semaglutide.

According to the terms of the agreement, Novo Holdings will acquire all outstanding shares of Catalent for $63.50 per share in cash. This acquisition price represents a 16.5% premium over the closing price of Catalent's common stock as of February 2, 2024, and a 47.5% premium over the 60-day volume-weighted average price as of February 2, 2024.

This merger is expected to be completed by the end of 2024, subject to customary closing conditions, including the approval of Catalent shareholders and the receipt of required regulatory approvals. Prior to the completion of the acquisition, Catalent will continue to operate independently, separate from Novo Holdings and Novo Nordisk; after the transaction is completed, Catalent’s stock will no longer be traded on the New York Stock Exchange, and Novo Nordisk will fulfill all customer obligations at three Catalent sites.

Novo Holdings is a holding and investment company, and one of the major shareholders of Novo Nordisk, owning 76.9% of the voting shares of Novo Nordisk. At the same time, Novo Holdings is a wholly-owned subsidiary of the Novo Nordisk Foundation, responsible for managing the foundation's assets and wealth. In addition, Novo Holdings is a world-leading life science investor, investing in life science companies at various stages of development. As of the end of 2022, Novo Holdings had total assets of 108 billion euros (approximately 116 billion US dollars).

The acquisition target, Catalent, is a global contract development and manufacturing organization (CDMO) headquartered in Somerset, New Jersey, providing drug delivery technologies, drug development, drug manufacturing, biologics, gene therapies, and consumer health products to life sciences companies worldwide. The company was founded in 2007 and went public in July 2014.According to the 2020 revenue, Catalent, along with two other CDMO companies, ranked among the top three in the global CDMO industry. In 2021, its highest market value once reached 22.091 billion US dollars.。

Catalent's "brilliance" stems from its strong comprehensive strength. Catalent once had a team of nearly 19,000 experts, including more than 3,000 scientists and technicians. Additionally, it has over 50 production bases across five continents globally, helping more than 1,500 partners plan and launch over 150 new products each year, supplying approximately 70 billion doses of nearly 8,000 products annually. Catalent's revenue reached $4.83 billion in 2022, a year-on-year increase of 21%, securing its place in the top 10 of the 2023 global CRO rankings.

However, the good times didn't last long. Since 2022, Catalent's revenue and stock price have successively declined. In recent years, its market value has dropped by over 50%, currently standing at only $9.84 billion. Previously, Catalent released its financial report for 2023 (fiscal year period: July 1, 2022 – June 30, 2023), showing total revenue of $4.276 billion, a year-on-year decrease of 11%; net loss of $232 million, expanding by 146% year-on-year.

In order to survive, Catalent also attempted layoffs. On November 30, 2022, Catalent was cutting approximately 600 jobs at its major manufacturing plants in Maryland, Texas, and Bloomington, Indiana. Additionally, according to foreign media reports, on February 6, 2023, Danaher Corporation expressed interest in acquiring Catalent. Following this news, Catalent's stock price rose by about 20%, reaching its highest level since November 2022, with a market value exceeding $10 billion. However, the deal ultimately did not go through.

It is worth noting that,Catalent has long had a close cooperative relationship with Novo Nordisk.The three production bases involved in this transaction are factories specializing in aseptic filling of pharmaceuticals, located in Italy, Belgium, and the United States. Previously, they were responsible for filling Novo Nordisk's obesity drug Wegovy into auto-injection pens.

However, in July 2023, Catalent's Belgian plant responsible for this filling operation was shut down again due to equipment failure. A similar incident occurred in 2021. The two shutdowns caused delays in the market supply of Wegovy throughout 2022 and in 2023.

In 2017, Novo Nordisk's semaglutide was approved by the FDA for the treatment of type 2 diabetes, marking the opening of Novo Nordisk's century-long main battlefield in the GLP-1 market. Since the approval of Wegovy, the injectable weight management formulation of semaglutide, for long-term weight management in 2021, Wegovy has gained explosive popularity.

Data can prove it. According to Novo Nordisk's 2023 financial report, the company's total revenue for the year reached 232.261 billion Danish kroner (approximately 33.771 billion US dollars), representing a year-on-year increase of 31%.Among these, the cumulative sales of GLP-1 drugs for glycemic control and weight reduction reached 164.764 billion Danish kroner (approximately 23.933 billion US dollars), accounting for about 70% of the company's total sales. Wegovy achieved sales of 31.343 billion Danish kroner (approximately 4.548 billion US dollars), representing a year-on-year increase of 407%.。

However, the火爆出圈 brings another problem: capacity shortage. Since being approved for weight loss indications, the supply of Wegovy has been limited, even leading to the phenomenon of obese patients using Ozempic (injectable hypoglycemic drug) as a substitute, causing diabetic patients to be一度无药可用.

To this end, Novo Nordisk began expanding its production capacity in 2017. Currently, it has five strategic production bases worldwide, located in Denmark, the United States, France, Brazil, and China, with nearly 20,000 employees in the production department. It has also commissioned multiple CDMO companies to ensure the production capacity of its own semaglutide drug. However, with the global explosion in demand for semaglutide, production capacity still falls short.

Therefore, since 2023, Novo Nordisk has frequently expanded its existing production facilities and has announced investments in multiple production bases.：

On June 12, 2023, a planned investment of 15.9 billion Danish kroner (approximately 16.697 billion yuan) will be used to expand the existing Active Pharmaceutical Ingredient (API) production facilities of the company located in Denmark.

On November 10, 2023, a planned investment of over 42 billion Danish kroner (approximately 44.1 billion yuan) was announced to expand its factory located in Denmark, which will be used for producing the current and future portfolio of products for severe chronic diseases.

On November 28, 2023, an investment of over 16 billion Danish kroner (approximately 16.8 billion yuan) was announced to expand the existing production facilities for severe chronic disease-related pharmaceutical products at the company’s site in Chartres, France. The construction project is expected to be completed between 2026 and 2028, which will increase the production capacity of multiple products, including several types of GLP-1 products.

However, according to the announcement, these construction projects are not expected to be completed until at least 2028, which cannot address Novo Nordisk's current capacity shortage.

Besides,Novo Nordisk also faces the impact brought by its "fated rival" Eli Lilly.。

November 8, 2023Lilly Announces FDA Approval of Its GLP-1/GIP Dual Receptor Agonist Zepbound (Tirzepatide) Injection for Market Launch, for the treatment of adults with a BMI of 30 or higher, as well as adults with a BMI of 27 or higher who also suffer from weight-related conditions such as hypertension, type 2 diabetes, obstructive sleep apnea, or cardiovascular disease.

Zepbound Becomes the First and Currently Only GLP-1R/GIPR Dual Agonist. Zepbound is currently priced at approximately $1,060, lower than Wegovy's $1,349. Additionally, clinical data from Eli Lilly suggests that Zepbound may offer more significant weight loss effects. From now on, Wegovy is no longer the only option for patients.

To address the risk of competitors seizing market share, Novo Nordisk urgently needs to seek alternative ways to quickly expand its production capacity, ensuring its position in the billion-dollar GLP-1 product market.

Therefore, Novo Holdings'不惜重金 acquisition of Catalent and its debt reflects the value placed on Catalent's comprehensive end-to-end service capabilities and over 50 global manufacturing facilities. This move aims to further expand Novo Nordisk's semaglutide production capacity and increase the market supply of Wegovy.

Novo Nordisk CEO Lars Fruergaard Jørgensen stated: "This acquisition complements our significant investments already made in active pharmaceutical ingredient facilities, and these plants will provide strategic flexibility to our existing supply network."Novo Nordisk stated that the deal will progressively enhance the company's production and filling capacity starting from 2026.。

By that time, who will come out on top in this showdown between Novo Nordisk and Eli Lilly? Let's wait and see!